Anika Therapeutics reported $13.32M in Cost of Sales for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbott ABT:US $ 4401M 63M
Acorda Therapeutics ACOR:US $ 11.96M 1.12M
Adamas Pharmaceuticals ADMS:US 597K 109K
Agenus AGEN:US $ 1.1M 301K
Anika Therapeutics ANIK:US $ 13.32M 2.63M
Clovis Oncology CLVS:US $ 17.88M 7.06M
Halozyme Therapeutics HALO:US $ 26.27M 20.7M
Heron Therapeutics HRTX:US $ 9.21M 0.18M
Immunogen IMGN:US $ 31793849155900M 31793849155900M
Insmed INSM:US $ 9.84M 1.02M
Integra Lifesciences IART:US $ 135.64M 632K
Johnson & Johnson JNJ:US $ 7036M 747M
Karyopharm Therapeutics KPTI:US $ 933K 119K
Ligand Pharmaceuticals LGND:US $ 8.15M 3.59M
Merit Medical Systems MMSI:US $ 137.02M 9.82M
Rigel Pharmaceuticals RIGL:US $ 0.32M 0M
Stryker SYK:US $ 1522M 33M
Surmodics SRDX:US $ 4.17M 0.43M
Veracyte VCYT:US $ 11.19M 0.82M
Zimmer Biomet Holdings Inc ZBH:US $ 516.4M 130.9M